半合成糖肽类抗生素LY191145对耐万古霉素肠球菌及其他革兰氏阳性菌的抗菌活性。
Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
作者信息
Nicas T I, Mullen D L, Flokowitsch J E, Preston D A, Snyder N J, Stratford R E, Cooper R D
机构信息
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA.
出版信息
Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7. doi: 10.1128/AAC.39.11.2585.
Abstract
LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin-resistant enterococci of < or = 4 micrograms/ml for 50% of isolates and < or = 16 micrograms/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 micrograms/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic-resistant gram-positive bacteria.
摘要
LY191145是一系列通过修饰糖肽抗生素LY264826而获得的对耐万古霉素肠球菌具有活性的化合物的原型。LY191145对50%的耐万古霉素和替考拉宁肠球菌分离株的最低抑菌浓度（MIC）≤4微克/毫升，对90%的分离株MIC≤16微克/毫升。其对耐万古霉素、对替考拉宁敏感的肠球菌的MIC为1至8微克/毫升。LY191145保留了其母体化合物对葡萄球菌和链球菌的强效活性。在小鼠感染模型中的体内研究证实了这些活性。该化合物表明半合成糖肽作为抗耐药革兰氏阳性菌药物的潜力。
相似文献
1
Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.半合成糖肽类抗生素LY191145对耐万古霉素肠球菌及其他革兰氏阳性菌的抗菌活性。
Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7. doi: 10.1128/AAC.39.11.2585.
2
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.源自LY264826的半合成糖肽类抗生素，对耐万古霉素肠球菌具有活性。
Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9. doi: 10.1128/AAC.40.9.2194.
3
European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.1995年革兰氏阳性菌的欧洲糖肽敏感性调查。欧洲糖肽耐药性调查研究组。
Diagn Microbiol Infect Dis. 1998 Aug;31(4):563-71. doi: 10.1016/s0732-8893(98)00053-4.
4
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.新型半合成糖肽LY333328的体外抗菌活性
Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72. doi: 10.1128/AAC.41.10.2165.
5
Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.一种新型糖肽类抗生素（LY333328）对肠球菌及其他耐药革兰氏阳性菌的活性。
J Antimicrob Chemother. 1997 Sep;40(3):423-5. doi: 10.1093/jac/40.3.423.
6
Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.多重耐药革兰氏阳性病原体。当前微生物学模式的最新情况。
Drugs. 1997;54 Suppl 6:11-20. doi: 10.2165/00003495-199700546-00005.
7
The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.新型糖肽类药物LY333328对耐万古霉素肠球菌临床分离株的体外活性
Adv Exp Med Biol. 1997;418:483-5. doi: 10.1007/978-1-4899-1825-3_115.
8
Glycopeptide tolerance in bacteria causing endocarditis.引起心内膜炎的细菌中的糖肽耐受性。
J Antimicrob Chemother. 1999 Jul;44(1):121-4. doi: 10.1093/jac/44.1.121.
9
Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.新型半合成糖肽衍生物AC98 - 6446（天然产物甘露肽霉素α的衍生物）与其他抗菌药物对革兰氏阳性临床分离株的体外比较活性。
Antimicrob Agents Chemother. 2004 Mar;48(3):739-46. doi: 10.1128/AAC.48.3.739-746.2004.
10
[Glycopeptide resistant enterococci. Occurrence, distribution, resistance transmission, significance].[耐糖肽肠球菌。发生情况、分布、耐药性传播、意义]
Wien Klin Wochenschr. 1997 May 9;109(9):293-300.
引用本文的文献
1
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.特拉万星通过与细胞壁前体脂II的靶向相互作用破坏细菌膜的功能完整性。
Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83. doi: 10.1128/AAC.01710-08. Epub 2009 May 26.
2
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.替考拉宁，一种多功能脂糖肽，可破坏耐甲氧西林金黄色葡萄球菌的细胞壁合成和细胞膜完整性。
Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34. doi: 10.1128/AAC.49.3.1127-1134.2005.
3
Intravenous mouse infection model for studying the pathology of Enterococcus faecalis infections.用于研究粪肠球菌感染病理学的静脉注射小鼠感染模型。
Infect Immun. 2003 Mar;71(3):1434-41. doi: 10.1128/IAI.71.3.1434-1441.2003.
4
Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies.糖肽类抗生素的六肽衍生物：作用机制研究工具
Antimicrob Agents Chemother. 2002 Aug;46(8):2344-8. doi: 10.1128/AAC.46.8.2344-2348.2002.
5
Antibiotic resistance: a current perspective.抗生素耐药性：当前视角
Br J Clin Pharmacol. 1999 Aug;48(2):109-24. doi: 10.1046/j.1365-2125.1999.00997.x.
6
Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.在多剂量体外药效学模型中，研究性糖肽类药物LY333328与每日一次庆大霉素联合使用对耐万古霉素屎肠球菌的协同作用。
Antimicrob Agents Chemother. 1999 Mar;43(3):592-7. doi: 10.1128/AAC.43.3.592.
7
Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.LY333328与氨苄西林单独及联合使用对耐万古霉素屎肠球菌的抑制和杀菌活性及抗生素后效应比较
Antimicrob Agents Chemother. 1998 Oct;42(10):2564-8. doi: 10.1128/AAC.42.10.2564.
8
Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands.荷兰住院患者及社区居民粪便中耐万古霉素肠球菌的携带情况。
J Clin Microbiol. 1997 Dec;35(12):3026-31. doi: 10.1128/jcm.35.12.3026-3031.1997.
9
The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics.寻找对多种抗生素耐药的细菌有效的抗菌剂。
Antimicrob Agents Chemother. 1997 Mar;41(3):497-503. doi: 10.1128/AAC.41.3.497.
10
Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues.一种半合成糖肽类抗生素与D-丙氨酰-D-丙氨酸和D-丙氨酰-D-乳酸残基的分子相互作用。
Antimicrob Agents Chemother. 1997 Jan;41(1):66-71. doi: 10.1128/AAC.41.1.66.
本文引用的文献
1
Structure-activity relationships of vancomycin-type glycopeptide antibiotics.万古霉素类糖肽抗生素的构效关系。
J Antibiot (Tokyo). 1993 Aug;46(8):1181-95. doi: 10.7164/antibiotics.46.1181.
2
Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.由对万古霉素、青霉素和庆大霉素高度耐药的屎肠球菌引起的医院感染暴发。
Clin Infect Dis. 1993 Jun;16(6):750-5. doi: 10.1093/clind/16.6.750.
3
Synthesis and antibacterial activity of N-acyl vancomycins.N-酰基万古霉素的合成及其抗菌活性
J Antibiot (Tokyo). 1988 Oct;41(10):1430-8. doi: 10.7164/antibiotics.41.1430.
4
Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose.单次静脉给药后雄性大鼠体内[14C]替考拉宁的药代动力学
Antimicrob Agents Chemother. 1986 Nov;30(5):733-8. doi: 10.1128/AAC.30.5.733.
5
Synthesis and antibacterial evaluation of N-alkyl vancomycins.N-烷基万古霉素的合成与抗菌评价
J Antibiot (Tokyo). 1989 Jan;42(1):63-72. doi: 10.7164/antibiotics.42.63.
6
Vancomycin-resistant enterococci.耐万古霉素肠球菌
Lancet. 1988;1(8575-6):57-8. doi: 10.1016/s0140-6736(88)91037-9.
7
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.糖肽类药物对耐万古霉素革兰氏阳性菌的活性。
Antimicrob Agents Chemother. 1989 Sep;33(9):1477-81. doi: 10.1128/AAC.33.9.1477.
8
The structural relationships of A82846B and its hydrolysis products with chloroorienticins A, B and C.A82846B及其水解产物与氯定向菌素A、B和C的结构关系。
J Antibiot (Tokyo). 1989 Sep;42(9):1438-40. doi: 10.7164/antibiotics.42.1438.
9
Inducible resistance to vancomycin in Enterococcus faecium D366.粪肠球菌D366对万古霉素的诱导性耐药
J Infect Dis. 1989 Jun;159(6):1095-104. doi: 10.1093/infdis/159.6.1095.
10
Transferable vancomycin and teicoplanin resistance in Enterococcus faecium.粪肠球菌中可转移的万古霉素和替考拉宁耐药性
Antimicrob Agents Chemother. 1989 Jan;33(1):10-5. doi: 10.1128/AAC.33.1.10.
Zotero 插件